Overview: 5-Alpha-Dihydrotestosterone TestIntroduction: The 5-Alpha-Dihydrotestosterone Test measures 5-alpha-dihydrotestosterone (DHT), a potent androgen, to diagnose hormonal disorders causing hair loss, prostate issues, or infertility. Aligned with 2023 American Urological Association guidelines, it uses an immunoassay for high sensitivity, aiding in the diagnosis of conditions like androgen insensitivity or benign prostatic hyperplasia. This test is critical for guiding hormone therapy or surgical interventions and improving outcomes in endocrinology and urology.
Other Names: 5-Alpha-DHT Assay, Dihydrotestosterone Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: DHT was identified as a key androgen in the 1960s. Immunoassays emerged in the 1980s, and by the 2000s, standardized assays improved clinical utility for hormonal disorder diagnostics.
Purpose: Diagnoses hormonal disorders, guides therapy for hair loss, prostate issues, or infertility in patients with androgen-related symptoms.
Test Parameters: 1. 5-Alpha-Dihydrotestosterone
Pretest Condition: Fasting for 10-12 hours is required. Collect serum, plasma, or saliva in the morning due to diurnal hormone variation. Report hair loss, prostate symptoms, or hormonal medications.
Specimen: 2-5 mL serum (SST), 2-4 mL plasma (EDTA), or 1-2 mL saliva (sterile container). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours, light-protected.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document hair loss, prostate issues, infertility, or family history of hormonal disorders. Include any hormonal treatments or medications.
Consent: Written consent is required, explaining the test's purpose, diagnostic implications, and potential need for hormone therapy.
Procedural Considerations: Employs an immunoassay (ELISA or radioimmunoassay) to measure DHT levels. Results are available in 1-2 days, facilitating rapid diagnosis.
Factors Affecting Result Accuracy: Hormonal medications or biotin supplements may cause false results. Hemolysis or improper storage can degrade sample quality. Morning collection ensures accuracy.
Clinical Significance: Elevated DHT levels suggest androgen excess, prompting therapy for prostate or hair loss issues. Low levels may indicate androgen insensitivity, requiring further testing.
Specialist Consultation: Consult an endocrinologist or urologist for result interpretation. Genetic counseling may be advised for familial disorders.
Additional Supporting Tests: Testosterone, sex hormone-binding globulin (SHBG), or prostate-specific antigen (PSA) to assess androgen status or prostate health.
Test Limitations: False results may occur with medications or improper sample timing. Mild imbalances may require additional assays for detection.
References: AUA Androgen Guidelines, 2023; Swerdloff RS, Journal of Clinical Endocrinology & Metabolism, 2022.
